Helicobacter pylori infection: What's new

Current Opinion in Infectious Diseases

Volumn 25, Issue 3, 2012, Pages 337-344

  Ruggiero, Paolo ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

CagA; gastric cancer; Helicobacter pylori; inflammation; T regulatory

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CAGA PROTEIN; CLARITHROMYCIN; HELICOBACTER PYLORI VACCINE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROBIOTIC AGENT; PROTEIN ASPP2; PROTEIN DERIVATIVE; PROTEIN P53; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WHEY PROTEIN CONCENTRATE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH; STOMACH CANCER; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; APOPTOSIS REGULATORY PROTEINS; BACTERIAL PROTEINS; BACTERIAL VACCINES; DRUG THERAPY, COMBINATION; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOTHERAPY; PROTON PUMP INHIBITORS;

EID: 84861021045     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283531f7c     Document Type: Review

References (91)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311-1315.
2. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39:353-365.
3. Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylorirelated diseases in developed countries: Recent developments and future implications. Microbes Infect 2003; 5:693-703.
4. Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5:705-713.
5. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of Helicobacter pylori infection: A follow-up study from infancy to adulthood. Lancet 2002; 359:931-935.
6. Rothenbacher D, Winkler M, Gonser T, et al. Role of infected parents in transmission of Helicobacter pylori to their children. Pediatr Infect Dis J 2002; 21:674-679.
7. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999; 282:2240-2245.
8. Zou QH, Li RQ. Helicobacter pylori in the oral cavity and gastric mucosa: A meta-analysis. J Oral Pathol Med 2011; 40:317-324.
9. Lin HC, Wu PY, Friedman M, et al. Difference of Helicobacter pylori colonization in recurrent inflammatory and simple hyperplastic tonsil tissues. Arch Otolaryngol Head Neck Surg 2010; 136:468-470.
10. Vilarinho S, Guimaraes NM, Ferreira RM, et al. Helicobacter pylori colonization of the adenotonsillar tissue: Fact or fiction? Int J Pediatr Otorhinolaryngol 2010; 74:807-811.
11. Kusano K, Inokuchi A, Fujimoto K, et al. Coccoid Helicobacter pylori exists in the palatine tonsils of patients with IgA nephropathy. J Gastroenterol 2010; 45:406-412.
12. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16 (Suppl 1): 1-9.
13. Sontag SJ. Guilty as charged: Bugs and drugs in gastric ulcer. Am J Gastroenterol 1997; 92:1255-1261.
14. Du MQ, Isaccson PG. Gastric MALT lymphoma: From aetiology to treatment. Lancet Oncol 2002; 3:97-104.
15. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784-789.
16. El-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681-691.
17. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113:15-24.
18. Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 2009; 60:3-21.
19. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29:459-464.
20. Persson C, Canedo P, Machado JC, et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173:259-270. This work further clarifies the role of host factors, such as polymorphisms in inflammatory genes, in determining the outcome of H. pylori infection.
21. Ruggiero P. Helicobacter pylori and inflammation. Curr Pharm Des 2010; 16:4225-4236.
22. Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000; 191:587-592.
23. Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996; 93:14648-14653.
24. Ogura K, Maeda S, Nakao M, et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 2000; 192:1601-1610.
25. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40:297-301.
26. Palli D, Masala G, Del Giudice G, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer 2007; 120:859-867.
27. Blaser MJ, Atherton JC. Helicobacter pylori persistence: Biology and disease. J Clin Invest 2004; 113:321-333.
28. Fischer W. Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J 2011; 278:1203-1212.
29. Terradot L, Waksman G. Architecture of the Helicobacter pylori Cag-type IV secretion system. FEBS J 2011; 278:1213-1222.
30. Cendron L, Zanotti G. Structural and functional aspects of unique type IV secretory components in the Helicobacter pylori cag-pathogenicity island. FEBS J 2011; 278:1223-1231.
31. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A 2000; 97:1263-1268.
32. Amieva MR, Vogelmann R, Covacci A, et al. Disruption of the epithelial apicaljunctional complex by Helicobacter pylori CagA. Science 2003; 300:1430-1434.
33. Stein M, Bagnoli F, Halenbeck R, et al. c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol 2002; 43:971-980.
34. Sohn SH, Lee YC. The genome-wide expression profile of gastric epithelial cells infected by naturally occurring cagA isogenic strains of Helicobacter pylori. Environ Toxicol Pharmacol 2011; 32:382-389.
35. Yamazaki S, Yamakawa A, Ito Y, et al. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis 2003; 187:334-337.
36. Bagnoli F, Buti L, Tompkins L, et al. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci U S A 2005; 102:16339-16344.
37. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A 2008; 105:1003-1008.
38. Suerbaum S, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol 2007; 5:441-452.
39. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: Ancient history, modern implications. J Clin Invest 2009; 119:2475-2487.
40. Delgado-Rosado G, Dominguez-Bello MG, Massey SE. Positive selection on a bacterial oncoprotein associated with gastric cancer. Gut Pathog 2011; 11:3:18.
41. Avilés-Jiménez F, Reyes-Leon A, Nieto-Patlán E, et al. In vivo expression of Helicobacter pylori virulence genes in patients with gastritis, ulcer, and gastric cancer. Infect Immun 2012; 80:594-601.
42. Wei J, Nagy TA, Vilgelm A, et al. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology 2010; 139:1333-1343.
43. Buti L, Spooner E, Van der Veen AG, et al. Helicobacter pylori cytotoxinassociated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A 2011; 108:9238-9243. This work elucidates in part the mechanisms that H. pylori uses to interfere with tumor suppression, finding that CagA binding to ASPP2 promotes p53 degradation thus inhibiting apoptosis of the host cell.
44. Poppe M, Feller SM, Rö mer G,Wessler S. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility. Oncogene 2007; 26:3462-3472.
45. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295:683-686.
46. Tsutsumi R, Higashi H, Higuchi M, et al. Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. J Biol Chem 2003; 278:3664-3670.
47. Higashi H, Nakaya A, Tsutsumi R, et al. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. J Biol Chem 2004; 279:17205-17216.
48. Tsutsumi R, Takahashi A, Azuma T, et al. Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA. Mol Cell Biol 2006; 26:261-276.
49. Oliveira MJ, Costa AM, Costa AC. CagA associates with c-Met, E-cadherin, and p120-catenin in a multiproteic complex that suppresses Helicobacter pylori-induced cell-invasive phenotype. J Infect Dis 2009; 200:745-755.
50. Snider JL, Cardelli JA. Helicobacter pylori induces cancer cell motility independent of the c-Met receptor. J Carcinog 2009; 8:7.
51. Chaturvedi R, Asim M, Romero-Gallo J, et al. Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gastroenterology 2011; 141:1696-1708. This work showed that CagA induces spermine oxidase resulting in DNA damage and apoptosis; however, a subpopulation of these cells are resistant to apoptosis and thus at high risk for malignant transformation.
52. Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci U S A 2011; 108:14944-14949. This work demonstrated that DNA damage by H. pylori can also occur independently of cag PAI.
53. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182:18-32.
54. Mills KH. Regulatory T cells: Friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-855.
55. Lundgren A, Suri-Payer E, Enarsson K, et al. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003; 71:1755-1762.
56. Cheng HH, Tseng GY, Yang HB, et al. Increased numbers of Foxp3-positive regulatory T cells in gastritis, peptic ulcer and gastric adenocarcinoma. World J Gastroenterol 2012; 18:34-43.
57. Lundgren A, Trollmo C, Edebo A, et al. Helicobacter pylori-specific CD4+ T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun 2005; 73:5612-5619.
58. Lundgren A, Strö mberg E, Sjö ling A, et al. Mucosal FOXP3-expressing CD4+CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005; 73:523-531.
59. Wu YY, Chen JH, Kao JT, et al. Expression of CD25(high) regulatory T cells and PD-1 in gastric infiltrating CD4(+) T lymphocytes in patients with Helicobacter pylori infection. Clin Vaccine Immunol 2011; 18:1198-1201.
60. Müller A, Solnick JV. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter 2011; 16 (Suppl 1):26-32.
61. Hitzler I, Oertli M, Becher B, et al. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology 2011; 141:186-196.
62. Kao JY, Zhang M, Miller MJ, et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 2010; 138:1046-1054.
63. Beswick EJ, Pinchuk IV, Earley RB, et al. Role of gastric epithelial cell-derived transforming growth factor beta in reduced CD4+ T cell proliferation and development of regulatory T cells during Helicobacter pylori infection. Infect Immun 2011; 79:2737-2745.
64. Arnold IC, Lee JY, Amieva MR, et al. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011; 140:199-209. This work sheds new light on the role of Treg, indicating that Treg-dependent tolerance, acquired upon infection at neonatal age, results in the absence of preneoplastic lesions in the stomach.
65. Freire de Melo F, Rocha AM, Rocha GA, et al. A regulatory instead of an IL-17 T response predominates in Helicobacter pylori-associated gastritis in children. Microbes Infect 2012 ;14:341-347. This work supports the hypothesis, also suggested by the studies in the mouse neonatal model [57], that the pathological outcome of H. pylori infection may differ according to the age at which the infection establishes.
66. Kido M, Watanabe N, Aoki N, et al. Dual roles of CagA protein in Helicobacter pylori-induced chronic gastritis in mice. Biochem Biophys Res Commun 2011; 412:266-272.
67. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12:275-278.
68. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter 2011; 16 (Suppl 1):53-58.
69. Gisbert JP, Calvet X. Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34:1255-1268.
70. Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther 2011; 9:581-588.
71. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 2011; 378:507-514.
72. Schmilovitz-Weiss H, Shalev T, Chechoulin Y, et al. High eradication rates of Helicobacter pylori infection following sequential therapy: The Israeli experience treating naïve patients. Helicobacter 2011; 16:229-233.
73. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16:139-145.
74. Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: A double-blind, randomized, controlled trial. J Pediatr 2011; 159:45-49.
75. Nadir I, Yonem O, Ozin Y, et al. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J 2011; 104: 102-105.
76. Liou JM, Chen CC, Chen MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial. J Antimicrob Chemother 2011; 66:1847-1852.
77. Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011; 16:234-240.
78. Furuta T, Kato M, Sugimoto M, et al. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Intern Med 2011; 50:369-374.
79. Malfertheiner P, Bazzoli F. Delchier et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905-913. An important study that demonstrates that in Europe the quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole can achieve high eradication rates, significantly better than those achievable with standard triple therapy.
80. Toros AB, Ince AT, Kesici B, et al. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter 2011; 16:225-228.
81. Ghadir MR, Shafaghi A, Iranikhah A, et al. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Turk J Gastroenterol 2011; 22:1-5.
82. Gokturk HS, Demir M, Unler GK, et al. Does long-term aspirin use have any effect on Helicobacter pylori eradication? Am J Med Sci 2011; 342:15-19. Interesting study that shows that, at least in Turkey, eradication rates with standard triple therapy are higher in long-term aspirin users.
83. Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011; 8:385-394.
84. Den Hoed CM, de Vries AC, Mensink PB, et al. Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial. Can J Gastroenterol 2011; 25:207-213.
85. Vítor JM, Vale FF. Alternative therapies for Helicobacter pylori: Probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63:153-164.
86. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: The role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45:960-966.
87. Bekar O, Yilmaz Y, Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food 2011; 14:344-347.
88. Medeiros JA, Gonçalves TM, Boyanova L, et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011; 30:555-559.
89. Yoon H, Kim N, Kim JY, et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011; 26:44-48.
90. Niv Y. H. pylori recurrence after successful eradication. World JGastroenterol 2008; 14:1477-1478.
91. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011; 8:133-140.